What is Ocular Therapeutix Debt-to-Equity?
Ocular Therapeutix's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.59 Mil. Ocular Therapeutix's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $81.80 Mil. Ocular Therapeutix's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $91.13 Mil.
Ocular Therapeutix's debt to equity for the quarter that ended in Dec. 2023 was 0.92.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Ocular Therapeutix's Debt-to-Equity or its related term are showing as below:
OCUL'
s Debt-to-Equity Range Over the Past 10 Years
Min: -16.35 Med: 0.68 Max: 1.82
Current: 0.92
During the past 12 years, the highest Debt-to-Equity Ratio of Ocular Therapeutix was 1.82. The lowest was -16.35. And the median was 0.68.
Ocular Therapeutix Debt-to-Equity Historical Data
The historical data trend for Ocular Therapeutix's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ocular Therapeutix Debt-to-Equity Chart
|
Ocular Therapeutix Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
Get a 7-Day Free Trial
|
|
|
-16.35 |
0.77 |
0.67 |
1.82 |
0.92 |
|
Ocular Therapeutix Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
1.82 |
6.65 |
20.98 |
10.57 |
0.92 |
Competitive Comparison of Ocular Therapeutix's Debt-to-Equity
For the Biotechnology subindustry, Ocular Therapeutix's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ocular Therapeutix's Debt-to-Equity Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ocular Therapeutix's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Ocular Therapeutix's Debt-to-Equity falls into.
Ocular Therapeutix Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Ocular Therapeutix's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Ocular Therapeutix's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ocular Therapeutix (Ocular Therapeutix) Business Description
Traded in Other Exchanges
Address
24 Crosby Drive, Bedford, MA, USA, 01730
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Ocular Therapeutix aims to offer medication to replace the existing eye-drop therapy regimen, with the aim of lasting weeks or months with a one-time product application. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
Executives
| Summer Road Llc |
10 percent owner |
207 6TH STREET, WEST PALM BEACH FL 33401 |
| Antony C. Mattessich |
director |
C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730 |
| Adrienne L Graves |
director |
125 STONE MOUNTAIN CIRCLE, NAPA CA 94558 |
| Rabia Gurses Ozden |
officer: Chief Medical Officer |
C/O AKOUOS, INC., 645 SUMMER STREET SUITE 200, BOSTON MA 02210 |
| Philip C. Strassburger |
officer: General Counsel |
24 CROSBY DRIVE, BEDFORD MA 01730 |
| Donald Notman |
officer: Chief Financial Officer |
C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730 |
| Christopher G White |
officer: Chief Business Officer |
C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451 |
| Jeffrey S. Heier |
director |
C/O OCULAR THERAPEUTIX, INC., 34 CROSBY DR., SUITE 105, BEDFORD MA 01730 |
| Merilee Raines |
director |
IDEXX LABORATORIES, INC., ONE IDEXX DRIVE, WESTBROOK ME 04092 |
| Lindstrom Richard L Md |
director |
2811 WESTWOOD PL, WAYZATA MN 55391 |
| Opaleye Management Inc. |
10 percent owner |
ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108 |
| Patricia Kitchen |
officer: Chief Operations Officer |
C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730 |
| Leslie J. Williams |
director |
C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730 |
| Seung Suh Hong |
director |
C/O OCULAR THERAPEUTIX, INC., 15 CROSBY DRIVE, BEDFORD MA 01730 |
| Amarpreet Sawhney |
director, 10 percent owner, officer: President and CEO |
C/O OCULAR THERAPEUTIX, INC., 36 CROSBY DRIVE, SUITE 101, BEDFORD MA 01730 |
Ocular Therapeutix (Ocular Therapeutix) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
OCUL has been successfully added to your